Sitemap
Pages
News
- 1-Year Outcomes Following Transfemoral Transseptal Transcatheter Mitral Valve Replacement: The HighLife TSMVR Feasibility Study - JACC Interventions
- AVAM - Bordeaux (France) May 31 - June 2
- AVAM - Bordeaux (France), October 2-4
- CSI - Frankfurt (Germany), June 28-July 1
- CVIS - Tucson, February 16-17
- DGK – Mannheim (Germany) April 12 - 16
- EuroPCR – Paris (France) May 16 - 19
- HighLife appoints Dr. Martin Rothman as independent member of the board
- HighLife appoints Jose Calle Gordo as Chairman of the Board
- HighLife appoints Prof. Stephen Brecker Chief Medical Officer
- HighLife closes €12.3 million financing round led by Sofinnova Partners
- HighLife Closes a €32 Million Round B Financing
- HighLife launches a new Large Annulus Valve in ongoing clinical studies for patients suffering from Mitral Regurgitation
- HighLife Receives IDE Approval to Initiate US Pivotal Clinical Study for treatment of Mitral Regurgitation
- HighLife Receives ISO 13485 Certification of its Quality Management System
- HighLife successfully initiates its clinical feasibility phase
- HighLife Successfully Initiates its Clinical Study in Europe
- HighLife welcomes Stefan Pilz as new Chief Executive Officer
- HighLife’s TSMVR System and Clinical Study progress featured at EuroPCR 2021
- HighLife’s TSMVR Technology successfully used for the first time in China
- London Valves, November 19 - 21
- Paris Echo (France) May 31-June 2
- Peijia Medical and HighLife Enter Into a License and Technology Transfer Agreement for Trans-septalMitral Valve Replacement in Greater China
- TCT - San Francisco, October 23-26
- TCT - Washington (USA), October 27-30
- TVT - Phoenix (USA), June 7-10
- VI Partners invests in Highlife Medical